News Roche hails 4 year NICE access deal for Gazyvaro NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the dru
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
